ClinicalTrials.gg
CompletedNCT00762177Updated Mar 23, 2011Results posted

Investigate Oral Bacteria in Adult Population

A Phase 3 interventional study of Fluoride and Fluoride, Triclosan in Oral Bacteria, sponsored by Colgate Palmolive. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-23.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To compare the antimicrobial efficacy of three dentifrices on oral bacteria

02

Conditions studied

  • Oral Bacteria
03

In context

Lead sponsor

Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females in good general health aged 18 to 70 years.
  • A willingness to read, understand, and sign the Form after the nature of the study has been fully explained to them. Subject should demonstrate a willingness to comply with all study procedures and sampling schedules.
  • A minimum of 20 natural teeth with facial and lingual scorable surfaces.
  • Adequate oral hygiene and no signs of oral neglect.
  • Good periodontal health. Enrolled subjects will have periodontal pockets no greater than 5 mm.
  • Gingival and plaque indices will also be measured during the first visit. Subjects with gingival index greater than or equal to 1.5 (Lobene Index) and plaque index greater than or equal to 1.5 (Turesky modification of Quigley-Hein Index) will be enrolled.

Exclusion criteria

Exclusion Criteria:

  • History of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses. Allergy to personal care/consumer products or their ingredients. Previous known allergy to dental materials, particularly to acrylic-like materials used to fabricate the stent device (this is a highly unlikely occurrence).
  • Teeth that are grossly carious, fully crowned or extensively restored on facial and/or lingual surfaces, orthodontically banded, abutments, or third molars
  • Difficulty having dental impressions taken such as excessive gagging.
  • History of diabetes or hepatic or renal disease, or other serious medical conditions or transmittable diseases, e.g. heart disease or AIDS.
  • History of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures.
  • Subjects on antibiotic, antiinflammatory or anticoagulant therapy during the month preceding the baseline exam.
  • Significant oral soft tissue pathology, systemically related gingival enlargement, severe gingivitis (based on a visual examinations).
  • History of active severe periodontal disease with bleeding gums and loose teeth.
  • Gross dental caries, severe generalized cervical abrasion and/or enamel abrasion, large fractured or temporary restorations (based on visual examinations).will not be included in the tooth count.
  • Fixed or removable orthodontic appliance or removable partial dentures.
  • Participation in a dental plaque/gingivitis clinical study involving oral care products, within the last 30 days. History of dental prophylaxis or treatments in the past month.
  • Self reported pregnancy or lactation.
  • History or current use of objects to pierce the lips or tongue.
  • Subjects known to be an alcoholic, or a recovering alcoholic.
  • History or current use of recreational drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Placebo comparator
    A -Control

    fluoride toothpaste

    Drug: Fluoride

  • Experimental
    B Experimental toothpaste

    Stannous fluoride toothpaste

    Drug: Stannous Fluoride

  • Active comparator
    C- positive control

    fluoride/triclosan/copolymer toothpaste

    Drug: Fluoride, Triclosan

Interventions

  • DrugFluoride

    Brush twice a day for 14 days

    Also known as: Crest Anti-Cavity toothpaste

  • DrugFluoride, Triclosan

    Drug pages: Fluorides · Triclosan

    Brush twice daily for 14 days

    Also known as: Total toothpaste

  • Brush twice daily for 14 days

06

What researchers measure

Primary outcomes

  1. Antimicrobial Species in Plaque(Actinomyces)

    After 14 days of study product use, dental plaque was scraped from the subject's teeth. The plaque was placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

    Time frame: 14 days

  2. Antimicrobial Species in Saliva(Actinomyces)

    Saliva was collected, after 14 days of product use, by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

    Time frame: 14 days

  3. Antimicrobial Species on the Tongue(Actinomycetes)

    After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

    Time frame: 14 days

  4. Antimicrobial Species on the Cheek(Actinomyces)

    After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

    Time frame: 14 days

  5. Antimicrobial Species in Plaque(Total Anaerobic)

    After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar

    Time frame: 14 days

  6. Antimicrobial Species in Saliva(Total Anaerobic)

    After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar

    Time frame: 14 days

  7. Antimicrobial Species in Tongue(Total Anaerobic)

    After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar.

    Time frame: 14 days

  8. Antimicrobial Species on the Cheek(Total Anaerobic)

    After 14 day of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar.

    Time frame: 14 days

  9. Antimicrobial Species in Plaque(Fusobacteria)

    After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

    Time frame: 14 days

  10. Antimicrobial Species in Saliva(Fusobacteria)

    After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

    Time frame: 14 days

  11. Antimicrobial Species in Tongue(Fusobacteria)

    After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

    Time frame: 14 days

  12. Antimicrobial Species on the Cheek(Fusobacteria)

    After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

    Time frame: 14 days

  13. Antimicrobial Species in Plaque(Oral Streptococci)

    After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.

    Time frame: 14 days

  14. Antimicrobial Species in Saliva(Oral Streptococci)

    After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.

    Time frame: 14 days

  15. Antimicrobial Species in Tongue(Oral Streptococci)

    After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.

    Time frame: 14 days

  16. Antimicrobial Species on the Cheek(Oral Streptococci)

    After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar

    Time frame: 14 days

  17. Antimicrobial Species in Plaque(Sulfur Bacteria)

    After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

    Time frame: 14 days

  18. Antimicrobial Species in Saliva(Sulfur Bacteria)

    After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

    Time frame: 14 days

  19. Antimicrobial Species in Tongue(Sulfur Bacteria)

    After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

    Time frame: 14 days

  20. Antimicrobial Species on the Cheek(Sulfur Bacteria)

    After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

    Time frame: 14 days

  21. Antimicrobial Species in Plaque(Veillonella)

    After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.

    Time frame: 14 days

  22. Antimicrobial Species in Saliva(Veillonella)

    After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on veillonella Agar.

    Time frame: 14 days

  23. Antimicrobial Species in Tongue(Veillonella)

    After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.

    Time frame: 14 days

  24. Antimicrobial Species on the Cheek(Veillonella)

    After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.

    Time frame: 14 days

07

Results

Posted Feb 14, 2011

Participant flow

subjects were recruited by the PI at the clinical site

1st Treatment Period
Participant flow — 1st Treatment Period
MilestonePlacebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rd
Started888
Completed888
Not completed000
Washout After 1st Treatment
Participant flow — Washout After 1st Treatment
MilestonePlacebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rd
Started888
Completed888
Not completed000
2nd Treatment Period
Participant flow — 2nd Treatment Period
MilestonePlacebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rd
Started888
Completed888
Not completed000
Washout After 2nd Treatment
Participant flow — Washout After 2nd Treatment
MilestonePlacebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rd
Started888
Completed888
Not completed000
3rd Treatment Period
Participant flow — 3rd Treatment Period
MilestonePlacebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rd
Started888
Completed888
Not completed000

Outcome measures

PrimaryAntimicrobial Species in Plaque(Actinomyces)

After 14 days of study product use, dental plaque was scraped from the subject's teeth. The plaque was placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Plaque(Actinomyces)
log CFU (Colony forming units)Placebo ToothpasteActive ComparatorExperimental
Antimicrobial Species in Plaque(Actinomyces)0.023 ± 0.04780.3881 ± 0.3220.0538 ± 0.0247
Statistical analysis
  • Placebo Toothpaste vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Saliva(Actinomyces)

Saliva was collected, after 14 days of product use, by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Saliva(Actinomyces)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Saliva(Actinomyces)0.016 ± 0.02360.3209 ± 0.03010.1116 ± 0.0272
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Tongue(Actinomycetes)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Tongue(Actinomycetes)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Tongue(Actinomycetes)-0.0132 ± 0.02290.2612 ± 0.0402-0.0536 ± 0.0262
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Cheek(Actinomyces)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Cheek(Actinomyces)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Cheek(Actinomyces)0.0099 ± 0.0270.2949 ± 0.0327-0.1875 ± 0.0354
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Plaque(Total Anaerobic)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Plaque(Total Anaerobic)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Plaque(Total Anaerobic)-0.0629 ± 0.04750.312 ± 0.04040.0762 ± 0.0547
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Saliva(Total Anaerobic)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Saliva(Total Anaerobic)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Saliva(Total Anaerobic)-0.0247 ± 0.02660.1505 ± 0.02980.05 ± 0.0331
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Tongue(Total Anaerobic)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Tongue(Total Anaerobic)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Tongue(Total Anaerobic)-0.0445 ± 0.05080.2691 ± 0.04030.0926 ± 0.0334
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Cheek(Total Anaerobic)

After 14 day of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Cheek(Total Anaerobic)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Cheek(Total Anaerobic)-0.0551 ± 0.02590.2009 ± 0.038-0.0531 ± 0.0346
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Plaque(Fusobacteria)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Plaque(Fusobacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Plaque(Fusobacteria)-0.2973 ± 0.05030.2703 ± 0.0431-0.0095 ± 0.038
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Saliva(Fusobacteria)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Saliva(Fusobacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Saliva(Fusobacteria)-0.0096 ± 0.02650.194 ± 0.03560.0539 ± 0.0311
Statistical analysis
  • Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Tongue(Fusobacteria)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Tongue(Fusobacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Tongue(Fusobacteria)-0.0742 ± 0.04160.377 ± 0.04950.1668 ± 0.048
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Cheek(Fusobacteria)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Cheek(Fusobacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Cheek(Fusobacteria)-0.0319 ± 0.04580.1887 ± 0.02510.111 ± 0.0265
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Plaque(Oral Streptococci)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Plaque(Oral Streptococci)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Plaque(Oral Streptococci)-0.0848 ± 0.04170.2593 ± 0.043-0.0096 ± 0.0358
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Saliva(Oral Streptococci)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Saliva(Oral Streptococci)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Saliva(Oral Streptococci)-0.0436 ± 0.03070.1445 ± 0.03050.087 ± 0.026
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Tongue(Oral Streptococci)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Tongue(Oral Streptococci)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Tongue(Oral Streptococci)-0.1284 ± 0.05370.2233 ± 0.03550.0525 ± 0.0358
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Cheek(Oral Streptococci)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Cheek(Oral Streptococci)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Cheek(Oral Streptococci)0.0126 ± 0.03260.2088 ± 0.0388-0.0251 ± 0.0309
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Plaque(Sulfur Bacteria)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Plaque(Sulfur Bacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Plaque(Sulfur Bacteria)0.0174 ± 0.06250.3083 ± 0.0424-0.0416 ± 0.057
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Saliva(Sulfur Bacteria)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Saliva(Sulfur Bacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Saliva(Sulfur Bacteria)-0.1213 ± 0.04940.1556 ± 0.0375-0.603 ± 0.0315
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Tongue(Sulfur Bacteria)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Tongue(Sulfur Bacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Tongue(Sulfur Bacteria)-0.083 ± 0.05640.2065 ± 0.0474-0.0248 ± 0.0511
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Cheek(Sulfur Bacteria)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Cheek(Sulfur Bacteria)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Cheek(Sulfur Bacteria)-0.1788 ± 0.03620.2036 ± 0.0581-0.0815 ± 0.0373
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Plaque(Veillonella)

After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Plaque(Veillonella)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Plaque(Veillonella)0.0007 ± 0.04780.3658 ± 0.03220.0316 ± 0.0247
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Saliva(Veillonella)

After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on veillonella Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Saliva(Veillonella)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Saliva(Veillonella)0.0167 ± 0.02130.3062 ± 0.03050.0901 ± 0.0261
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species in Tongue(Veillonella)

After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species in Tongue(Veillonella)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species in Tongue(Veillonella)-0.002 ± 0.02290.2724 ± 0.0402-0.0424 ± 0.0262
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05
PrimaryAntimicrobial Species on the Cheek(Veillonella)

After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.

Time frame:
14 days
Reported as:
Log mean · log CFU (Colony forming units)
Antimicrobial Species on the Cheek(Veillonella)
log CFU (Colony forming units)PlaceboActive ComparatorExperimental
Antimicrobial Species on the Cheek(Veillonella)-0.0732 ± 0.03510.2579 ± 0.0426-0.0676 ± 0.0294
Statistical analysis
  • Placebo vs Active Comparator vs Experimental · ANCOVA · p = 0.05

Adverse events

Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Fluoride Control—0/24 (0%)0/24 (0%)
Active Comparator—0/24 (0%)0/24 (0%)
Experimental—0/24 (0%)0/24 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rdTotal
<=18 years0000
Between 18 and 65 years88824
>=65 years0000
Age Continuous
Age Continuous(years)Placebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rdTotal
Mean39.87 ± 10.7240.12 ± 9.3836.5 ± 7.4638.83 ± 9.03
Sex: Female, Male
Sex: Female, Male(Participants)Placebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rdTotal
Female75416
Male1348
Region of Enrollment
Region of Enrollment(participants)Placebo 1st, Active Comparator 2nd and Experimental 3rdActive Comparator 1st, Experimental 2nd, Placebo 3rdExperimental 1st, Placebo 2nd, Active Comparator 3rdTotal
United States88824
08

Study locations

1 site
  • Department of Oral Biology
    Newark, New York 07103-2714, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 30, 2008
Start
May 2008
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Feb 14, 2011
Last update
Mar 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00762177
Lead sponsor
Colgate Palmolive
First posted
Sep 30, 2008
Start date
May 2008
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Feb 14, 2011
Last update
Mar 23, 2011

Study contacts

Daniel Fine, DDS
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion